XORTX Therapeutics Inc. (XRTX)
NASDAQ: XRTX · Real-Time Price · USD
1.350
-0.070 (-4.93%)
Nov 4, 2024, 4:00 PM EST - Market closed
XORTX Therapeutics Stock Forecast
XRTX's stock price has decreased by -56.05% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 1 analyst with a 12-month price forecast for XORTX Therapeutics stock has a target of 14, which predicts an increase of 937.04% from the current stock price of 1.35.
Analyst Consensus: Strong Buy
* Price targets were last updated on Jan 4, 2024.
Analyst Ratings
According to 1 stock analyst, the rating for XRTX is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Nov '23 | Dec '23 | Jan '24 |
---|---|---|---|
Strong Buy | 1 | 1 | 1 |
Buy | 0 | 0 | 0 |
Hold | 0 | 0 | 0 |
Sell | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 |
Total | 1 | 1 | 1 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Alliance Global Partners | Alliance Global Partners | Strong Buy Maintains $9 → $14 | Strong Buy | Maintains | $9 → $14 | +937.04% | Jan 4, 2024 |
Alliance Global Partners | Alliance Global Partners | Strong Buy Initiates $99 | Strong Buy | Initiates | $99 | +7,233.33% | Dec 9, 2021 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.39
from -1.09
EPS Next Year
-1.55
from -1.39
Revenue Forecast
Revenue | 2024 | 2025 |
---|---|---|
High | n/a | n/a |
Avg | n/a | n/a |
Low | n/a | n/a |
Revenue Growth
Revenue Growth | 2024 | 2025 |
---|---|---|
High | - | - |
Avg | - | - |
Low | - | - |
EPS Forecast
EPS | 2024 | 2025 |
---|---|---|
High | -1.16 | -1.00 |
Avg | -1.39 | -1.55 |
Low | -1.62 | -2.08 |
EPS Growth
EPS Growth | 2024 | 2025 |
---|---|---|
High | - | - |
Avg | - | - |
Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.